Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

  title={Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile},
  author={Alejandro Jara and Eduardo A. Undurraga and Cecilia Gonz{\'a}lez and Fabio Paredes and Tom{\'a}s Fontecilla and Gonzalo Jara and Alejandra Pizarro and Johanna Acevedo and Katherine Leo and Francisco Leon and Carlos Sans and Paulina Leighton and Pamela Su{\'a}rez and Heriberto E. Garc{\'i}a-Escorza and Rafael Araos},
  journal={The New England Journal of Medicine},
Abstract Background Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021. Methods We used a prospective national cohort, including participants 16 years of… 

Figures and Tables from this paper

Effectiveness of the inactivated COVID-19 vaccine (CoronaVac) in adult population in Indonesia

Two-dose of inactivated CoronaVac vaccine showed high effectiveness against laboratory confirmed CO VID-19 infection, hospitalization, and death associated with COVID-19 among adults aged [≥]18 years.

Effectiveness of Four Vaccines in Preventing SARS-CoV-2 Infection in Kazakhstan

The authors' analysis demonstrates high effectiveness of COVID-19 vaccines against infection in Almaty similar to other observational studies, and higher cumulative hazard of breakthrough among people >60 years of age and during variant surges warrants targeted booster vaccination campaigns.

Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis

SARS-CoV-2 vaccines have reassuring safety and could effectively reduce the death, severe cases, symptomatic cases, and infections resulting from SARS- covirus disease 2019 across the world.

Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required

While antibody positivity remained above 90% in the 6th month after two doses of inactivated vaccine in HCWs, the median titers of neutralizing antibodies decreased rapidly, and the decrease was more rapid and significant in those with no history of prior COVID-19 infection.

SARS-CoV-2 vaccines breakthrough infection hospitalizations after one dose in Libya: cohort study

One dose of the three different types of vaccines had decreased the virus transmission across people and mortality rate until 10 weeks after the first dose, highlighting the dramatic success of the early months of the nation's coronavirus vaccines rollout.

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study

Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021

  • A. MarraJ. Miraglia L. V. Rizzo
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2022
While 2 doses of ChAdOx1 or CoronaVac vaccines prevent COVID-19, the addition of a Pfizer/BioNTech booster provided significantly more protection.

Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco

A Sinopharm vaccine is highly protective against serious SARS-CoV-2 infection under real-world conditions and protection remained high and stable during the first three months following the second dose and decreases slightly beyond the fourth month especially beyond 60 years.

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease

A systematic review of COVID-19 vaccines as of August 2021, which includes efficacy data from Phase 3 clinical trials for 13 vaccines within the WHO Emergency Use Listing evaluation process and real-world effectiveness for 5 vaccines with observational studies meeting inclusion criteria.

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

It is unprecedented in pandemic control history to develop a dozen successful vaccines in the first year and to immunize over half of the global population in the second year, due to the efforts of the scientific community, biopharmaceutical industry, and regulatory agencies worldwide.



BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.

Development of an inactivated vaccine candidate for SARS-CoV-2

Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.

Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study

Administration of at least one dose of CoronaVac showed effectiveness against symptomatic SARS-CoV-2 infection in the setting of epidemic P.1 transmission, underscoring the need to increase vaccination efforts in response to the spread of this variant in Brazil and globally.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.

Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People

A single dose of the BNT162b2 mRNA and ChAdOx1 vaccines resulted in substantial reductions in the risk of COVID-19 related hospitalisation in Scotland.